
  
    
      
        Background_NNP
        Despite_IN continuing_VBG decreases_NNS in_IN incidence_NN and_CC mortality_NN
        rates_NNS ,_, cancers_NNS of_IN the_DT colon_NN and_CC rectum_NN remain_VBP the_DT third_JJ
        leading_VBG cause_NN of_IN cancer_NN deaths_NNS in_IN the_DT North_NNP America_NNP [_NN 1_CD 2_CD ]_NN
        ._. The_DT decline_NN in_IN incidence_NN ,_, and_CC hence_RB mortality_NN ,_, from_IN
        colorectal_NN cancers_NNS is_VBZ most_RBS likely_JJ attributable_JJ to_TO an_DT
        increase_NN in_IN recommendations_NNS to_TO perform_VB routine_JJ screening_NN on_IN
        average_JJ risk_NN individuals_NNS and_CC to_TO improved_VBN screening_NN
        techniques_NNS [_NN 2_CD ]_NN ._. In_IN addition_NN ,_, there_EX is_VBZ ever_RB advancing_VBG
        knowledge_NN into_IN the_DT pathogenic_JJ mechanism_NN of_IN cancer_NN and_CC
        resulting_VBG strides_NNS in_IN the_DT development_NN of_IN more_JJR efficacious_JJ
        therapies_NNS ._.
        In_IN recent_JJ years_NNS it_PRP has_VBZ become_VBN evident_JJ that_DT nonsteroidal_NN
        anti-inflammatory_JJ drugs_NNS (_( NSAIDs_NNP )_) represent_VB a_DT potential_JJ
        class_NN of_IN cancer_NN chemotherapeutic_JJ agents_NNS ._. The_DT utility_NN of_IN
        NSAIDs_NNP ,_, in_IN particular_JJ aspirin_NN ,_, in_IN the_DT treatment_NN of_IN colon_NN
        cancer_NN has_VBZ stemmed_VBN from_IN studies_NNS conducted_VBD both_DT in_IN animals_NNS [_NN
        3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD ]_NN and_CC humans_NNS [_NN 12_CD 13_CD 14_CD 15_CD ]_NN ._. Evidence_NN
        from_IN human_JJ studies_NNS has_VBZ largely_RB come_VBN from_IN epidemiological_JJ
        data_NNS indicating_VBG that_DT aspirin_NN and_CC other_JJ NSAIDs_NNP can_MD reduce_VB
        the_DT relative_JJ risk_NN of_IN developing_VBG colorectal_NN cancer_NN by_IN
        approximately_RB 40_CD -_: 50_CD %_NN [_NN 13_CD 14_CD 15_CD 16_CD ]_NN ._. The_DT utility_NN of_IN
        NSAIDs_NNP in_IN the_DT cancer_NN therapeutics_NNS is_VBZ not_RB limited_VBN to_TO
        prevention_NN strategies_NNS ._. The_DT NSAID_NNP sulindac_NN has_VBZ been_VBN shown_VBN to_TO
        cause_VB regression_NN of_IN colorectal_NN adenomas_NNS of_IN patients_NNS with_IN
        hereditary_JJ forms_NNS of_IN polyposis_NNS (_( Familial_NNP Adenomatous_NNP
        Polyposis_NNP (_( FAP_NNP )_) and_CC Gardner_NNP 's_POS Syndrome_NNP )_) [_NN 17_CD 18_CD 19_CD ]_NN and_CC in_IN
        sporadic_JJ colorectal_NN adenomas_NNS [_NN 20_CD ]_NN ._. In_IN addition_NN ,_, case_NN
        reports_NNS have_VBP demonstrated_VBN that_DT indomethacin_NN and_CC sulindac_NN
        were_VBD effective_JJ co-therapy_JJ agents_NNS in_IN the_DT treatment_NN of_IN
        desmoid_NN tumours_NNS [_NN 21_CD 22_CD ]_NN ._. Finally_RB ,_, the_DT inclusion_NN either_CC
        of_IN indomethacin_NN ,_, naproxen_NN or_CC sulindac_NN in_IN the_DT chemotherapy_NN
        regiment_NN of_IN gastric_JJ carcinoma_NN patients_NNS resulted_VBD in_IN a_DT
        significant_JJ increase_NN in_IN survival_NN ;_: 30_CD months_NNS versus_CC 6_CD months_NNS
        when_WRB NSAIDs_NNP included_VBN in_IN treatment_NN regime_NN [_NN 22_CD ]_NN ._.
        The_DT anti-neoplastic_JJ properties_NNS of_IN NSAIDs_NNP can_MD be_VB
        duplicated_VBN in_IN animal_NN models_NNS (_( mainly_RB rodent_NN )_) of_IN colon_NN
        cancer_NN ._. The_DT two_CD most_RBS commonly_RB used_VBN are_VBP the_DT multiple_JJ
        intestinal_NN neoplasia_NN (_( 
        Min_NNP /_NN +_NN )_) mouse_NN and_CC the_DT chemically_RB
        (_( azoxymethane_NN )_) -_: induced_VBN rat_NN models_NNS ._. In_IN both_DT models_NNS ,_, NSAID_NNP
        administration_NN has_VBZ been_VBN reported_VBN to_TO significantly_RB attenuate_NN
        tumour_NN number_NN and_CC size_NN when_WRB provided_VBN either_CC as_IN a_DT preventive_JJ
        [_NN 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD ]_NN or_CC treatment_NN [_NN 3_CD 6_CD 11_CD ]_NN agent_NN ._. The_DT 
        Min_NNP /_NN +_NN model_NN has_VBZ received_VBN great_JJ
        favour_NN because_IN it_PRP contains_VBZ a_DT mutation_NN in_IN the_DT 
        Apc_NNP gene_NN ,_, which_WDT is_VBZ homologous_RB to_TO the_DT
        human_JJ adenomatous_JJ polyposis_NNS coli_NNS (_( APC_NNP )_) gene_NN [_NN 23_CD ]_NN ._.
        Defects_NNP in_IN the_DT APC_NNP tumour_NN suppressor_NN gene_NN are_VBP thought_VBN to_TO
        play_VB a_DT role_NN in_IN greater_JJR than_IN 70_CD %_NN of_IN all_DT colorectal_NN cancers_NNS
        and_CC is_VBZ responsible_JJ for_IN inherited_VBN syndromes_NNS of_IN polyposis_NNS
        (_( FAP_NNP and_CC Gardner_NNP 's_POS )_) [_NN 24_CD 25_CD ]_NN ._. Furthermore_RB ,_, in_IN humans_NNS the_DT
        majority_NN of_IN colorectal_NN cancers_NNS arise_VBP from_IN adenomatous_JJ
        polyps_NNS [_NN 26_CD ]_NN ._.
        Polyposis_NNP in_IN the_DT 
        Min_NNP /_NN +_NN mouse_NN differs_VBZ slightly_RB from_IN
        the_DT human_JJ condition_NN of_IN FAP_NNP ._. Polyps_NNP (_( multiple_JJ )_) are_VBP generally_RB
        localized_VBN to_TO the_DT small_JJ intestine_NN in_IN 
        Min_NNP /_NN +_NN mice_NNS ,_, opposed_VBN to_TO the_DT colons_NNS of_IN
        FAP_NNP suffers_VBZ [_NN 27_CD ]_NN ._. In_IN 
        Min_NNP /_NN +_NN mice_NNS adenoma_NN formation_NN is_VBZ
        thought_VBN to_TO occur_VB within_IN the_DT first_JJ few_JJ weeks_NNS of_IN life_NN ,_, with_IN a_DT
        full_JJ compliment_NN of_IN adenomas_NNS being_VBG attained_VBN by_IN approximately_RB
        9_CD weeks_NNS of_IN age_NN (_( 60_CD -_: 67_CD days_NNS of_IN age_NN )_) [_NN 6_CD 28_CD ]_NN ._. Following_VBG
        this_DT time_NN ,_, adenoma_NN multiplicity_NN is_VBZ thought_VBN not_RB to_TO change_VB ,_,
        however_RB ,_, adenoma_NN size_NN may_MD still_RB increase_VB [_NN 6_CD 28_CD ]_NN ._. 
        Min_NNP /_NN +_NN mice_NNS are_VBP also_RB normally_RB found_VBD
        to_TO develop_VB anaemia_NN by_IN 60_CD days_NNS of_IN age_NN and_CC possess_VBP a_DT
        shortened_VBN life_NN span_NN of_IN roughly_RB 120_CD days_NNS (_( 17_CD weeks_NNS )_) [_NN 29_CD ]_NN
        ._.
        Aspirin_NNP most_RBS likely_JJ represents_VBZ the_DT best_RBS known_VBN and_CC
        frequently_RB purchased_VBN NSAID_NNP [_NN 26_CD ]_NN ._. It_PRP is_VBZ also_RB the_DT NSAID_NNP
        normally_RB cited_VBD in_IN epidemiological_JJ studies_NNS assessing_VBG the_DT
        chemopreventive_JJ efficacy_NN of_IN NSAIDs_NNP [_NN 16_CD ]_NN ,_, but_CC yet_RB the_DT
        utility_NN of_IN aspirin_NN in_IN the_DT treatment_NN of_IN 
        established_VBN colorectal_NN cancer_NN has_VBZ not_RB
        been_VBN determined_VBN ._. We_PRP therefore_RB wanted_VBD to_TO determine_VB if_IN
        aspirin_NN is_VBZ able_JJ to_TO reduce_VB the_DT number_NN and_CC size_NN of_IN adenomas_NNS
        in_IN 
        Min_NNP /_NN +_NN mice_NNS with_IN 
        established_VBN polyposis_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Animals_NNS
          
          Min_NNP /_NN +_NN (_( C_NNP 57_CD BL_NNP /_NN 6_CD J-_NNP 
          Apc_NNP 
          
            Min_NNP 
           )_) and_CC wild_JJ type_NN (_( C_NNP 57_CD BL_NNP /_NN 6_CD J_NNP )_) mice_NNS were_VBD purchased_VBN from_IN
          Jackson_NNP Laboratories_NNPS (_( Bar_NNP Harbor_NNP ,_, ME_NNP )_) ._. Mice_NNS were_VBD housed_VBN
          in_IN a_DT room_NN with_IN a_DT 12_CD hour_NN light-dark_JJ cycle_NN and_CC had_VBD free_JJ
          access_NN to_TO food_NN (_( LabDiet_NNP ,_, ®_NN Prolab_NNP ®_NN RMH_NNP 3500_CD ,_, Purina_NNP Mills_NNP ,_,
          Inc_NNP ._. ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) and_CC water_NN during_IN the_DT entire_JJ
          protocol_NN ._. All_DT procedures_NNS were_VBD approved_VBN by_IN the_DT Albany_NNP
          Medical_NNP College_NNP Institutional_NNP Animal_NNP Care_NNP and_CC Use_NNP
          Committee_NNP (_( IACUC_NNP )_) ._.
        
        
          Treatment_NNP protocol_NN
          
          Min_NNP /_NN +_NN mice_NNS were_VBD treated_VBN for_IN a_DT
          period_NN of_IN 28_CD days_NNS either_CC with_IN vehicle_NN or_CC aspirin_NN (_( 25_CD
          mg_NN /_NN kg_NN /_NN day_NN )_) ._. Dose_NNP of_IN aspirin_NN correlates_NNS to_TO previous_JJ work_NN
          conducted_VBN by_IN Mahmoud_NNP et_CC al_NN ._. [_NN 9_CD ]_NN ,_, which_WDT demonstrated_VBD
          that_IN 0_CD ._. 5_CD mg_NN of_IN aspirin_NN per_IN day_NN was_VBD chemopreventive_JJ in_IN 
          Min_NNP /_NN +_NN mice_NNS ._. Aspirin_NNP was_VBD initially_RB
          dissolved_VBN in_IN dimethyl_NN sulfoxide_NN (_( DMSO_NNP ;_: 5_CD %_NN by_IN final_JJ
          volume_NN )_) and_CC then_RB diluted_VBN to_TO the_DT desired_VBN concentration_NN (_( 5_CD
          mg_NN /_NN mL_NN )_) with_IN 0_CD ._. 5_CD %_NN carboxymethylcellulose_NN (_( CMC_NNP )_) ._. Both_DT
          aspirin_NN and_CC drug_NN vehicle_NN were_VBD orally_RB administered_VBN via_IN a_DT
          22_CD -_: gauge_VB feeding_NN needle_NN (_( Kent_NNP Scientific_NNP Co_NNP ._. ,_, Litchfield_NNP ,_,
          CT_NNP )_) attached_VBN to_TO a_DT 1_CD cc_NN syringe_NN ._. Compounds_NNP were_VBD delivered_VBN
          at_IN a_DT rate_NN of_IN 5_CD mL_NN /_NN kg_NN body_NN weight_NN ._. A_DT diluted_VBN concentration_NN
          was_VBD used_VBN to_TO aid_VB in_IN drug_NN solubility_NN and_CC accuracy_NN of_IN drug_NN
          administration_NN ._.
          Treatment_NNP began_VBD at_IN 12_CD weeks_NNS (_( 84_CD days_NNS )_) of_IN age_NN and_CC
          concluded_VBD at_IN 16_CD weeks_NNS (_( 112_CD days_NNS )_) of_IN age_NN ._. Following_VBG
          completion_NN of_IN the_DT treatment_NN period_NN ,_, mice_NNS were_VBD euthanized_JJ
          with_IN sodium_NN pentobarbital_NN (_( Nembutal_NNP ®_NN ;_: 50_CD mg_NN /_NN kg_NN i_NNP ._. m_NN ._. )_) and_CC
          the_DT entire_JJ gastrointestinal_NN (_( GI_NNP )_) tract_NN was_VBD removed_VBN ._. The_DT
          GI_NNP tract_NN was_VBD segregated_VBD into_IN stomach_NN ,_, small_JJ intestine_NN and_CC
          colon_NN ,_, and_CC placed_VBD into_IN 10_CD %_NN phosphate_NN buffered_JJ formalin_NN
          for_IN fixation_NN ._. A_DT portion_NN of_IN liver_NN tissue_NN was_VBD also_RB obtained_VBN
          to_TO determine_VB cyclooxygenase_NN (_( COX_NNP )_) activity_NN ._.
        
        
          Assessment_NNP of_IN polyp_NN number_NN and_CC size_NN
          Following_VBG a_DT 24_CD hour_NN fixation_NN period_NN ,_, the_DT stomach_NN and_CC
          intestines_NNS were_VBD opened_VBN longitudinally_RB and_CC rinsed_JJ with_IN
          phosphate_NN buffered_JJ saline_NN (_( PBS_NNP ,_, pH_NN 7_CD ._. 4_LS )_) ._. Tissues_NNPS were_VBD
          then_RB pinned_VBN flat_JJ on_IN wax_NN blocks_NNS and_CC covered_VBN with_IN trypan_NN
          blue_JJ (_( 0_CD ._. 4_LS %_NN solution_NN )_) for_IN 10_CD minutes_NNS and_CC rinsed_JJ with_IN PBS_NNP
          to_TO improve_VB polyp_NN contrast_NN ._. Polyp_NNP numbers_NNS were_VBD determined_VBN
          by_IN manual_JJ count_NN via_IN use_NN of_IN a_DT dissecting_VBG microscope_NN
          (_( Bausch_NNP &_CC Lomb_NNP ,_, Rochester_NNP ,_, NY_NNP )_) by_IN an_DT observer_NN unaware_JJ
          of_IN the_DT treatment_NN the_DT mice_NNS had_VBD received_VBN ._. The_DT entire_JJ GI_NNP
          tract_NN for_IN each_DT animal_NN was_VBD then_RB photographed_VBN using_VBG a_DT video_NN
          camera_NN (_( JVC_NNP ,_, Wayne_NNP ,_, NJ_NNP )_) outfitted_JJ with_IN a_DT Navitar_NNP Zoom_NNP
          7000_CD macro_NN lens_NN (_( Technical_NNP Instruments_NNP ,_, San_NNP Francisco_NNP ,_,
          CA_NNP )_) ._. Images_NNP were_VBD captured_VBN and_CC analysed_JJ by_IN use_NN of_IN
          computerised_JJ software_NN (_( Scion_NNP Image_NN ,_, Scion_NNP Corporation_NNP ,_,
          Frederick_NNP ,_, MD_NNP )_) ._. Individual_JJ polyp_NN diameters_NNS were_VBD
          calculated_VBN from_IN their_PRP$ measured_VBN areas_NNS ._.
        
        
          Immunohistochemical_NNP detection_NN of_IN apoptosis_NNS
          Sections_NNP of_IN formalin-fixed_JJ small_JJ intestinal_NN tissues_NNS ,_,
          approximately_RB 15_CD cm_NN in_IN length_NN ,_, were_VBD rolled_VBN upon_IN
          themselves_PRP with_IN the_DT mucosal_NN surface_NN facing_VBG outwards_NNS ._.
          Tissue_NNP sections_NNS were_VBD then_RB processed_VBN and_CC embedded_VBN in_IN
          paraffin_NN using_VBG routine_JJ histological_JJ techniques_NNS ._. Small_JJ
          intestinal_NN tissue_NN was_VBD sectioned_JJ at_IN 4_CD μm_NN and_CC immobilised_JJ
          on_IN slides_NNS ._.
          Apoptotic_NNP cells_NNS were_VBD labelled_JJ 
          in_IN situ_NN by_IN use_NN of_IN a_DT commercially_RB
          available_JJ detection_NN kit_NN (_( TACS_NNP 2_CD TdT_NNP DAB_NNP kit_NN ,_, Trevigen_NNP ,_,
          Inc_NNP ._. ,_, Gaithersburg_NNP ,_, MD_NNP )_) ._. Samples_NNP were_VBD processed_VBN according_VBG
          to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._. Briefly_NNP ,_, paraffin_NN wax_NN
          was_VBD removed_VBN from_IN slides_NNS by_IN heating_VBG at_IN 57_CD °_NN C_NNP for_IN 20_CD
          minutes_NNS ,_, followed_VBN by_IN two_CD subsequent_JJ washes_NNS in_IN 100_CD %_NN
          Xylene_NNP ._. Slides_NNS were_VBD then_RB rehydrated_JJ by_IN sequential_NN washes_NNS
          in_IN ethanol_NN (_( 100_CD %_NN ,_, 95_CD %_NN and_CC 70_CD %_NN ,_, 1_CD ×_NN 5_CD min_NN ._. )_) ,_, deionized_JJ
          water_NN (_( 2_CD ×_NN 2_CD min_NN ._. )_) and_CC PBS_NNP (_( 1_CD ×_NN 10_CD min_NN ._. )_) ._. Following_VBG
          rehydration_NN ,_, tissue_NN was_VBD proteolytically_RB treated_VBN
          (_( Proteinase_NNP K_NNP ,_, 20_CD μg_NN /_NN mL_NN )_) for_IN 15_CD minutes_NNS ._. Endogenous_NNP
          peroxidase_NN activity_NN was_VBD quenched_JJ by_IN immersing_VBG slides_NNS in_IN a_DT
          2_CD %_NN hydrogen_NN peroxide_NN (_( H_NNP 
          2_CD O_NNP 
          2_LS )_) solution_NN ._. Excess_NNP peroxide_NN solution_NN
          was_VBD removed_VBN by_IN tapping_VBG and_CC slides_NNS were_VBD then_RB immediately_RB
          submersed_JJ in_IN labelling_VBG buffer_NN (_( 50_CD mM_NN Tris_NNP ,_, pH_NN 7_CD ._. 5_CD ;_: 5_CD mM_NN
          MgCl_NNP 
          2_CD ;_: 0_CD ._. 06_CD mM_NN 2_CD -_: Mercaptoethanesulfonic_NNP
          Acid_NNP ;_: 0_CD ._. 05_CD mg_NN /_NN mL_NN BSA_NNP )_) for_IN 2_CD minutes_NNS ._. Slides_NNS were_VBD removed_VBN
          from_IN labelling_VBG buffer_NN and_CC excess_JJ buffer_NN surrounding_VBG the_DT
          tissue_NN was_VBD wiped_VBN away_RB ._. Samples_NNP were_VBD covered_VBN with_IN
          labelling_VBG reaction_NN mixture_NN (_( 50_CD mM_NN Tris_NNP ,_, pH_NN 7_CD ._. 5_CD ;_: 5_CD mM_NN MgCl_NNP
          
          2_LS ;_: 0_CD ._. 06_CD mM_NN 2_CD -_: Mercaptoethanesulfonic_NNP
          Acid_NNP ;_: 0_CD ._. 05_CD mg_NN /_NN mL_NN BSA_NNP ;_: 1_CD mM_NN CoCl_NNP 
          2_CD ;_: 0_CD ._. 008_CD mM_NN TdT_NNP dNTP_NN mix_NN ;_: 300_CD U_NNP /_NN mL_NN
          TdT_NNP )_) and_CC incubated_JJ for_IN 60_CD minutes_NNS in_IN a_DT humidified_JJ chamber_NN
          (_( 37_CD °_NN C_NNP )_) ._. The_DT labelling_VBG reaction_NN was_VBD terminated_VBN by_IN
          transferring_VBG the_DT slides_NNS to_TO 50_CD mL_NN of_IN stop_NN buffer_NN (_( 10_CD mM_NN
          EDTA_NNP ,_, pH_NN 8_CD ._. 0_CD )_) for_IN 5_CD minutes_NNS ._. Excess_NNP stop_VB buffer_NN was_VBD
          removed_VBN by_IN washing_VBG the_DT slide_NN once_RB in_IN 50_CD mL_NN of_IN PBS_NNP for_IN 2_CD
          minutes_NNS ._.
          Detection_NNP of_IN labelled_JJ cells_NNS was_VBD carried_VBN out_IN via_IN the_DT
          conversion_NN of_IN diaminobenzidine_NN (_( DAB_NNP )_) by_IN
          streptavidin-horseradish_JJ peroxidase_NN (_( strep-_NN HRP_NNP )_) ._. Labelled_NNP
          samples_NNS were_VBD covered_VBN with_IN 100_CD μL_NN strep-_NN HRP_NNP solution_NN and_CC
          incubated_JJ for_IN 10_CD minutes_NNS ._. Excess_NNP strep-_NN HRP_NNP was_VBD removed_VBN by_IN
          tapping_VBG prior_RB to_TO washing_VBG the_DT slide_NN twice_RB in_IN 50_CD mL_NN of_IN PBS_NNP ._.
          Slides_NNS were_VBD placed_VBN into_IN 50_CD mL_NN of_IN DAB_NNP solution_NN (_( 0_CD ._. 5_LS mg_NN /_NN mL_NN
          DAB_NNP and_CC 0_CD ._. 03_CD %_NN H_NNP 
          2_CD O_NNP 
          2_CD in_IN PBS_NNP )_) for_IN 5_CD to_TO 10_CD minutes_NNS ._. Slides_NNS
          were_VBD briefly_NN rinsed_JJ twice_RB with_IN deionized_JJ water_NN ,_, prior_RB to_TO
          counterstaining_VBG with_IN methyl_NN green_JJ ._.
          Apoptotic_NNP cells_NNS were_VBD counted_VBN manually_RB by_IN an_DT observer_NN
          unaware_JJ of_IN the_DT treatment_NN regime_NN and_CC were_VBD normalised_JJ based_VBN
          on_IN polyp_NN area_NN ._. Polyp_NNP area_NN was_VBD determined_VBN from_IN captured_VBN
          images_NNS (_( Nikon_NNP ,_, Labophot-_NNP 2_CD microscope_NN fitted_JJ with_IN a_DT JVC_NNP
          video_NN camera_NN )_) using_VBG the_DT same_JJ computerised_JJ software_NN stated_VBN
          above_IN ._.
        
        
          Assessment_NNP of_IN cyclooxygenase_NN activity_NN
          Cyclooxygenase_NNP activity_NN was_VBD assessed_VBN 
          ex_FW vivo_NN in_IN hepatic_JJ tissue_NN following_VBG
          a_DT previously_RB described_VBN method_NN [_NN 30_CD ]_NN ._. Briefly_NNP ,_, mice_NNS were_VBD
          euthanized_JJ 3_CD hours_NNS following_VBG the_DT final_JJ dose_NN of_IN vehicle_NN or_CC
          aspirin_NN and_CC a_DT sample_NN of_IN liver_NN tissue_NN (_( ~_NN 100_CD mg_NN )_) was_VBD
          obtained_VBN ._. The_DT samples_NNS were_VBD then_RB placed_VBN into_IN
          microcentrifuge_NN tubes_NNS containing_VBG 1_CD mL_NN of_IN sodium_NN phosphate_NN
          buffer_NN (_( 10_CD mmol_NN /_NN L_NNP ,_, pH_NN 7_CD ._. 4_LS )_) and_CC finely_RB minced_JJ with_IN
          scissors_NNS for_IN 15_CD seconds_NNS ._. Samples_NNP were_VBD then_RB incubated_JJ for_IN
          20_CD minutes_NNS at_IN 37_CD °_NN C_NNP in_IN a_DT shaking_VBG water_NN bath_NN ._. Following_VBG the_DT
          incubation_NN period_NN ,_, samples_NNS were_VBD centrifuged_JJ at_IN 9_CD 000_CD ×_NN 
          g_SYM for_IN 30_CD seconds_NNS and_CC the_DT
          supernatants_NNS collected_VBN ._. Supernatants_NNP were_VBD flash_VBP frozen_VBN in_IN
          liquid_JJ nitrogen_NN and_CC stored_VBD at_IN -_: 80_CD °_NN C_NNP for_IN subsequent_JJ
          determination_NN of_IN prostaglandin_NN E_NNP 
          2_CD (_( PGE_NNP 
          2_LS )_) content_NN ._. PGE_NNP 
          2_CD concentrations_NNS were_VBD determined_VBN using_VBG
          a_DT commercially_RB available_JJ ELISA_NNP assay_NN (_( Cayman_NNP Chemical_NNP
          Company_NNP ,_, Ann_NNP Arbor_NNP ,_, MI_NNP )_) ._.
        
        
          Materials_NNS
          Aspirin_NNP (_( acetylsalicylic_JJ acid_NN )_) ,_,
          carboxymethylcellulose_NN ,_, dimethyl_NN sulfoxide_NN and_CC hydrogen_NN
          peroxide_NN were_VBD obtained_VBN from_IN Sigma_NNP Chemical_NNP Co_NNP ._. (_( St_NNP ._.
          Louis_NNP ,_, MO_NNP )_) ._. Histology_NNP supplies_NNS and_CC reagents_NNS were_VBD
          purchased_VBN from_IN Fisher_NNP Scientific_NNP (_( Springfield_NNP ,_, NJ_NNP )_) ._.
        
        
          Statistical_NNP analysis_NN
          All_DT data_NNS are_VBP expressed_VBN as_IN the_DT mean_JJ ±_NN SEM_NNP ._. Comparison_NNP
          among_IN groups_NNS of_IN data_NNS were_VBD made_VBN using_VBG either_CC an_DT unpaired_JJ
          Student_NNP 's_POS 
          t_NN test_NN or_CC one-way_JJ analysis_NN of_IN
          variance_NN (_( ANOVA_NNP )_) ,_, followed_VBN by_IN a_DT Bonferroni_NNP 's_POS post_NN test_NN ._.
          Differences_NNS between_IN groups_NNS were_VBD considered_VBN significant_JJ
          with_IN a_DT p_NN value_NN of_IN less_JJR than_IN 0_CD ._. 05_CD ._.
        
      
      
        Results_NNS
        
          Polyp_NNP number_NN and_CC size_NN
          Sixteen_NNP week_NN old_JJ 
          Min_NNP /_NN +_NN mice_NNS possessed_VBD approximately_RB
          63_CD ±_NN 9_CD polyps_NNS (_( n_NN =_SYM 13_CD )_) within_IN their_PRP$ small_JJ and_CC large_JJ
          intestine_NN ,_, combined_VBN ._. Approximately_RB 97_CD %_NN of_IN the_DT polyps_NNS
          present_RB were_VBD located_VBN in_IN the_DT small_JJ intestine_NN (_( table_NN 1_LS )_) ._.
          Once_RB daily_JJ oral_JJ administration_NN of_IN aspirin_NN (_( 25_CD mg_NN /_NN kg_NN )_) for_IN
          four_CD weeks_NNS had_VBD no_DT effect_NN on_IN the_DT number_NN of_IN polyps_NNS in_IN the_DT
          intestinal_NN tract_NN of_IN 
          Min_NNP /_NN +_NN mice_NNS ._. Aspirin-treated_NNP mice_NNS
          contained_VBD 62_CD ±_NN 8_CD small_JJ intestinal_NN polyps_NNS and_CC 2_CD ._. 5_CD ±_NN 0_CD ._. 4_CD
          large_JJ intestinal_NN polyps_NNS (_( table_NN 1_LS )_) ._. Concurrent_JJ with_IN the_DT
          above_JJ findings_NNS ,_, no_DT significant_JJ differences_NNS were_VBD seen_VBN in_IN
          total_JJ adenoma_NN area_NN or_CC average_JJ adenoma_NN size_NN ._. Adenomas_NNP in_IN
          the_DT small_JJ intestine_NN had_VBD an_DT average_JJ diameter_NN of_IN 1_CD ._. 64_CD ±_NN
          0_CD ._. 22_CD mm_NN and_CC 1_CD ._. 73_CD ±_NN 0_CD ._. 14_CD mm_NN for_IN vehicle-_NN and_CC
          aspirin-treated_JJ 
          Min_NNP /_NN +_NN mice_NNS ,_, respectively_RB ._. Similar_JJ
          findings_NNS were_VBD seen_VBN within_IN large_JJ intestine_NN (_( table_NN 1_LS )_) ._.
          Furthermore_RB ,_, no_DT changes_NNS were_VBD seen_VBN in_IN the_DT distribution_NN of_IN
          adenomas_NNS when_WRB classified_VBN according_VBG to_TO diameter_NN (_( figure_NN
          1_LS )_) ._. Small_JJ intestinal_NN adenomas_NNS were_VBD less_JJR than_IN 4_CD mm_NN in_IN
          diameter_NN ,_, with_IN the_DT approximately_RB 75_CD %_NN being_VBG 1_CD -_: 3_CD mm_NN in_IN
          diameter_NN ._. Large_JJ intestinal_NN adenomas_NNS as_RB large_JJ as_IN 5_CD -_: 6_CD mm_NN in_IN
          diameter_NN were_VBD occasionally_RB seen_VBN ._. Aspirin_NNP treatment_NN had_VBD no_DT
          effect_NN on_IN adenoma_NN size_NN distribution_NN and_CC both_DT profiles_NNS
          were_VBD essentially_RB identical_JJ to_TO those_DT of_IN the_DT
          vehicle-treated_JJ group_NN (_( figure_NN 1_LS )_) ._.
        
        
          Cyclooxygenase_NNP activity_NN and_CC apoptosis_NNS
          Vehicle-treated_NNP 
          Min_NNP /_NN +_NN mice_NNS displayed_VBD a_DT 2_CD -_: fold_VB
          increase_NN in_IN their_PRP$ capacity_NN to_TO generate_VB PGE_NNP 
          2_CD when_WRB compared_VBN to_TO wild_JJ type_NN mice_NNS
          (_( figure_NN 2_LS )_) ._. Once_RB daily_JJ aspirin_NN (_( 25_CD mg_NN /_NN kg_NN p_NN ._. o_NN ._. )_)
          administration_NN to_TO 
          Min_NNP /_NN +_NN mice_NNS caused_VBD a_DT significant_JJ
          reduction_NN in_IN the_DT ability_NN of_IN liver_NN to_TO generate_VB PGE_NNP 
          2_CD compared_VBN to_TO vehicle-treated_JJ 
          Min_NNP /_NN +_NN mice_NNS (_( figure_NN 2_LS )_) ._. PGE_NNP 
          2_CD levels_NNS (_( 3_CD ._. 8_CD ±_NN 1_CD ._. 0_CD pg_NN /_NN mg_NN tissue_NN )_) in_IN
          the_DT aspirin-treated_JJ mice_NNS were_VBD comparable_JJ to_TO those_DT seen_VBN in_IN
          wild_JJ type_NN mice_NNS ._.
          Aspirin_NNP administration_NN also_RB resulted_VBD in_IN a_DT significant_JJ
          increase_NN in_IN the_DT number_NN of_IN apoptotic_JJ cells_NNS found_VBD in_IN small_JJ
          intestinal_NN adenomas_NNS (_( figure_NN 3_LS )_) ._. Vehicle-treated_NNP 
          Min_NNP /_NN +_NN mice_NNS contained_VBD 32_CD ._. 2_LS ±_NN 5_CD ._. 6_CD
          apoptotic_JJ cells_NNS per_IN area_NN (_( mm_NN 2_LS )_) of_IN adenoma_NN ._. The_DT number_NN of_IN
          apoptotic_JJ cells_NNS per_IN adenoma_NN area_NN was_VBD twice_RB (_( 67_CD ._. 6_CD ±_NN 16_CD ._. 7_CD
          cells_NNS per_IN mm_NN 2_CD ;_: p_NN =_SYM 0_CD ._. 05_CD )_) as_IN great_JJ in_IN the_DT aspirin-treated_JJ
          group_NN ._.
        
        
          Overall_RB welfare_NN
          The_DT quality_NN of_IN life_NN of_IN the_DT 
          Min_NNP /_NN +_NN mice_NNS ,_, as_IN assessed_VBN by_IN change_NN
          in_IN body_NN weight_NN ,_, hematocrit_NN level_NN and_CC overall_JJ survival_NN ,_,
          was_VBD not_RB altered_VBN in_IN the_DT aspirin-treated_JJ group_NN compared_VBN to_TO
          the_DT vehicle-treated_JJ group_NN (_( table_NN 2_LS )_) ._. Wild_NNP type_NN animals_NNS
          treated_VBN with_IN vehicle_NN weighed_VBD initially_RB 23_CD ._. 6_CD ±_NN 1_CD ._. 6_CD g_SYM and_CC
          gained_VBD approximately_RB 2_CD ._. 9_CD ±_NN 1_CD ._. 9_CD g_SYM over_IN the_DT 4_CD -_: week_NN period_NN ._.
          Vehicle-_NNP and_CC aspirin-treated_JJ 
          Min_NNP /_NN +_NN mice_NNS initially_RB weighed_VBD 24_CD ._. 6_CD
          ±_NN 1_CD ._. 1_CD g_SYM and_CC 24_CD ._. 0_CD ±_NN 1_CD ._. 1_CD g_SYM ,_, respectively_RB ._. Both_DT 
          Min_NNP /_NN +_NN groups_NNS failed_VBD to_TO gain_VB
          weight_NN ,_, rather_RB a_DT modest_JJ decrease_NN in_IN body_NN weight_NN was_VBD noted_VBN
          over_IN the_DT study_NN period_NN (_( -_: 0_CD ._. 9_CD ±_NN 1_CD ._. 4_CD g_SYM and_CC -_: 0_CD ._. 1_LS ±_NN 1_CD ._. 1_CD g_SYM ,_,
          respectively_RB )_) ._. Both_DT the_DT vehicle-_NN and_CC aspirin-treated_JJ
          groups_NNS were_VBD found_VBN to_TO be_VB anemic_JJ based_VBN upon_IN hematocrit_NN
          values_NNS (_( table_NN 2_LS )_) ._. Anaemia_NNP is_VBZ characteristic_NN of_IN the_DT model_NN
          [_NN 29_CD ]_NN ._. Both_DT treatment_NN groups_NNS displayed_VBD hematocrit_NN
          levels_NNS 25_CD -_: 30_CD %_NN lower_JJR than_IN expected_VBN values_NNS ._. Aspirin_NNP
          treatment_NN did_VBD not_RB improve_VB or_CC worsen_VB the_DT anaemia_NN (_( table_NN
          2_LS )_) ._. Wild_NNP type_NN (_( C_NNP 57_CD BL_NNP /_NN 6_CD J_NNP ,_, background_NN strain_NN of_IN 
          Min_NNP /_NN +_NN mice_NNS )_) are_VBP referenced_JJ to_TO have_VB
          hematocrit_NN levels_NNS of_IN 44_CD ±_NN 0_CD ._. 4_CD %_NN [_NN 31_CD ]_NN ._.
          Survival_NNP rate_NN of_IN the_DT 
          Min_NNP /_NN +_NN mice_NNS was_VBD greater_JJR than_IN 95_CD %_NN ._.
          One_CD animal_NN had_VBD to_TO be_VB sacrificed_JJ prior_RB (_( 2_CD days_NNS )_) to_TO the_DT
          completion_NN of_IN the_DT study_NN and_CC was_VBD in_IN the_DT vehicle_NN treatment_NN
          group_NN (_( table_NN 2_LS )_) ._. Post-mortem_NNP examination_NN revealed_VBD a_DT total_NN
          of_IN 87_CD polyps_NNS (_( 82_CD small_JJ and_CC 5_CD large_JJ intestinal_NN )_) ._. Data_NNP
          obtained_VBD from_IN this_DT animal_NN was_VBD not_RB included_VBN in_IN the_DT
          analysis_NN ._. In_IN addition_NN ,_, one_CD animal_NN was_VBD found_VBN to_TO possess_VB no_DT
          small_JJ or_CC large_JJ intestinal_NN polyps_NNS ._. The_DT animal_NN had_VBD been_VBN
          treated_VBN with_IN a_DT full_JJ regiment_NN of_IN aspirin_NN ,_, however_RB ,_, it_PRP was_VBD
          assumed_VBN not_RB to_TO possess_VB the_DT 
          Min_NNP /_NN +_NN genotype_NN and_CC was_VBD therefore_RB
          not_RB included_VBN in_IN data_NNS analysis_NN ._. A_DT wild_JJ type_NN genotype_NN was_VBD
          assumed_VBN ,_, since_IN no_DT existing_VBG data_NN suggests_VBZ or_CC indicates_VBZ
          that_DT aspirin_NN is_VBZ able_JJ to_TO cause_VB complete_JJ elimination_NN of_IN
          adenomas_NNS in_IN this_DT model_NN ._. The_DT animal_NN also_RB possessed_VBD a_DT
          normal_JJ hematocrit_NN value_NN of_IN 44_CD %_NN [_NN 31_CD ]_NN ._.
        
      
      
        Discussion_NNP
        The_DT American_NNP Cancer_NNP Society_NNP has_VBZ indicated_VBN that_DT cancer_NN
        incidence_NN rates_NNS are_VBP on_IN the_DT decline_NN ,_, however_RB ,_, they_PRP estimate_VBP
        that_IN greater_JJR than_IN 1_CD ._. 2_CD million_CD new_JJ cases_NNS will_MD be_VB diagnosed_VBN
        this_DT year_NN [_NN 1_CD ]_NN ._. Of_IN these_DT new_JJ cases_NNS ,_, it_PRP is_VBZ expected_VBN that_IN
        colorectal_NN cancers_NNS will_MD comprise_VB approximately_RB 10_CD -_: 11_CD %_NN [_NN 1_CD ]_NN
        ._. With_IN staggering_JJ numbers_NNS as_IN these_DT ,_, it_PRP is_VBZ not_RB surprising_JJ
        that_DT chemoprevention_NN has_VBZ been_VBN proposed_VBN as_IN a_DT viable_JJ strategy_NN
        to_TO fight_VB cancer_NN ._. Among_IN the_DT leading_VBG therapeutic_JJ agents_NNS in_IN
        colorectal_NN cancer_NN prevention_NN are_VBP NSAIDs_NNP ,_, especially_RB
        aspirin_NN ._. Epidemiological_NNP studies_NNS have_VBP indicated_VBN that_IN the_DT
        frequent_JJ ,_, long_JJ term_NN use_NN of_IN aspirin_NN could_MD reduce_VB the_DT
        relative_JJ risk_NN of_IN developing_VBG colorectal_NN cancer_NN by_IN 40_CD -_: 50_CD %_NN [_NN
        13_CD 14_CD 15_CD 32_CD ]_NN ._. Despite_IN the_DT wealth_NN of_IN information_NN regarding_VBG
        the_DT chemopreventive_JJ ability_NN of_IN aspirin_NN ,_, information_NN to_TO
        indicate_VB aspirin_NN 's_POS utility_NN in_IN a_DT therapeutic_JJ modality_NN is_VBZ
        lacking_VBG ._. To_TO date_NN no_DT studies_NNS or_CC case_NN reports_NNS have_VBP examined_VBN
        the_DT use_NN of_IN aspirin_NN in_IN the_DT treatment_NN of_IN FAP_NNP ,_, although_IN
        various_JJ clinical_JJ trials_NNS are_VBP under_IN way_NN [_NN 33_CD ]_NN ._. In_IN
        accordance_NN with_IN the_DT above_JJ data_NN ,_, studies_NNS conducted_VBN in_IN
        animals_NNS have_VBP always_RB employed_VBN a_DT prevention_NN strategy_NN as_RB well_RB
        [_NN 4_CD 7_CD 9_CD ]_NN ._. To_TO our_PRP$ knowledge_NN ,_, this_DT is_VBZ the_DT first_JJ study_NN to_TO
        examine_VB the_DT therapeutic_JJ potential_NN of_IN aspirin_NN in_IN a_DT rodent_NN
        model_NN of_IN colon_NN carcinogenesis_NNS ,_, in_IN particular_JJ ,_, the_DT 
        Min_NNP /_NN +_NN murine_NN model_NN of_IN polyposis_NNS ._. The_DT
        study_NN revealed_VBD that_DT treatment_NN of_IN 
        Min_NNP /_NN +_NN mice_NNS with_IN established_VBN
        polyposis_NNS with_IN aspirin_NN for_IN 4_CD weeks_NNS produce_VBP no_DT appreciable_JJ
        therapeutic_JJ effect_NN ._.
        While_IN the_DT evaluation_NN of_IN aspirin_NN in_IN the_DT 
        Min_NNP /_NN +_NN model_NN utilising_VBG a_DT therapeutic_JJ
        regime_NN is_VBZ lacking_VBG ,_, other_JJ NSAIDs_NNP (_( sulindac_NN ,_, flurbiprofen_NN ,_,
        piroxicam_NN and_CC celecoxib_NN )_) have_VBP been_VBN shown_VBN to_TO significantly_RB
        reduce_VB polyp_NN numbers_NNS when_WRB administered_VBN using_VBG similar_JJ
        protocols_NNS [_NN 6_CD 11_CD 34_CD 35_CD ]_NN ._. In_IN addition_NN ,_, three_CD recent_JJ
        reports_NNS have_VBP demonstrated_VBN a_DT lack_NN of_IN effect_NN of_IN aspirin_NN as_IN a_DT
        chemopreventive_JJ agent_NN in_IN 
        Min_NNP /_NN +_NN mice_NNS [_NN 36_CD 37_CD 38_CD ]_NN ._. Combined_VBN ,_,
        these_DT studies_NNS indicate_VBP that_IN the_DT 
        Min_NNP /_NN +_NN model_NN is_VBZ responsive_JJ to_TO NSAIDs_NNP
        other_JJ than_IN aspirin_NN when_WRB provided_VBN as_IN a_DT treatment_NN ._. They_PRP also_RB
        raise_VBP into_IN question_NN the_DT efficacy_NN of_IN aspirin_NN as_IN a_DT
        chemotherapeutic_JJ for_IN colon_NN cancer_NN ,_, and_CC perhaps_RB more_RBR
        specifically_RB ,_, familial_NN adenomatous_JJ polyposis_NNS ._.
        With_IN the_DT exemplary_JJ track_NN record_NN of_IN NSAIDs_NNP in_IN this_DT model_NN
        of_IN colon_NN cancer_NN ,_, why_WRB was_VBD a_DT lack_NN of_IN effect_NN seen_VBN in_IN this_DT
        model_NN ?_. Was_VBD it_PRP a_DT consequence_NN of_IN the_DT dose_NN of_IN aspirin_NN and_CC /_NN or_CC
        duration_NN of_IN treatment_NN used_VBN ?_. In_IN the_DT current_JJ study_NN ,_, mice_NNS
        received_VBD approximately_RB 500_CD μg_NN of_IN aspirin_NN per_IN day_NN ._. This_DT
        amount_NN of_IN aspirin_NN was_VBD found_VBN by_IN Mahmoud_NNP 
        et_CC al_NN ._. [_NN 9_CD ]_NN to_TO be_VB sufficient_JJ
        (_( significant_JJ )_) to_TO reduce_VB both_DT polyp_NN number_NN and_CC intestinal_NN
        prostaglandin_NN (_( PGE_NNP 
        2_LS )_) content_NN by_IN greater_JJR than_IN 45_CD %_NN when_WRB
        provided_VBN from_IN 5_CD -_: 6_CD weeks_NNS of_IN age_NN to_TO 16_CD weeks_NNS of_IN age_NN (_( i_NNP ._. e_SYM ._. ,_,
        chemopreventive_JJ regime_NN )_) ._. Barnes_NNP and_CC Lee_NNP [_NN 7_CD ]_NN have_VBP also_RB
        suggested_VBN that_IN the_DT maximal_NN tumour_NN suppression_NN for_IN aspirin_NN
        may_MD be_VB in_IN the_DT 50_CD %_NN range_NN ._. The_DT above_IN authors_NNS followed_VBD a_DT
        similar_JJ protocol_NN to_TO Mahmoud_NNP et_CC al_NN ._. [_NN 9_CD ]_NN ,_, but_CC employed_VBN far_RB
        greater_JJR doses_NNS of_IN aspirin_NN (_( 45_CD and_CC 90_CD mg_NN /_NN kg_NN /_NN day_NN )_) and_CC reported_VBD
        no_DT dose-response_JJ relationship_NN and_CC a_DT maximal_NN suppression_NN of_IN
        55_CD %_NN [_NN 7_CD ]_NN ._. Furthermore_RB ,_, in_IN the_DT rat_NN model_NN of_IN
        azoxymethane-induced_JJ colon_NN carcinogenesis_NNS ,_, aspirin_NN has_VBZ also_RB
        only_RB been_VBN found_VBN to_TO inhibit_VB aberrant_NN crypt_NN foci_NN and_CC tumour_NN
        development_NN by_IN no_RB more_JJR than_IN 65_CD %_NN [_NN 4_CD 39_CD ]_NN ._. Coincidentally_NNP ,_,
        epidemiological_JJ data_NNS also_RB report_VBP reductions_NNS in_IN the_DT 40_CD -_: 50_CD %_NN
        range_NN [_NN 13_CD 14_CD 15_CD 32_CD ]_NN ._. However_RB ,_, whether_IN this_DT can_MD be_VB used_VBN
        as_IN an_DT argument_NN to_TO support_VB the_DT notion_NN that_DT aspirin_NN is_VBZ only_RB
        able_JJ to_TO suppress_VB tumour_NN formation_NN by_IN 50_CD %_NN is_VBZ difficult_JJ to_TO
        extrapolate_NN because_IN two_CD different_JJ end_NN points_NNS are_VBP being_VBG
        examined_VBN (_( i_NNP ._. e_SYM ._. ,_, relative_JJ risk_NN versus_CC tumour_NN number_NN )_) ._.
        Finally_RB ,_, as_IN indicated_VBN earlier_RBR ,_, other_JJ studies_NNS have_VBP
        demonstrated_VBN that_IN doses_NNS of_IN NSAIDs_NNP other_JJ than_IN aspirin_NN which_WDT
        were_VBD found_VBN to_TO be_VB chemopreventive_JJ were_VBD able_JJ to_TO produce_VB
        similar_JJ reductions_NNS in_IN polyp_NN numbers_NNS when_WRB used_VBN in_IN a_DT
        treatment_NN regime_NN [_NN 6_CD 11_CD 34_CD 35_CD ]_NN ._. Chiu_NNP 
        et_CC al_NN ._. [_NN 6_CD ]_NN demonstrated_VBN that_IN 
        Min_NNP /_NN +_NN mice_NNS at_IN approximately_RB 11_CD weeks_NNS
        of_IN age_NN possessed_VBD roughly_RB 35_CD -_: 40_CD polyps_NNS and_CC that_DT treatment_NN
        (_( starting_VBG at_IN 11_CD weeks_NNS of_IN age_NN )_) for_IN as_RB little_JJ as_IN 4_CD days_NNS with_IN
        sulindac_NN produced_VBD a_DT 75_CD %_NN reduction_NN in_IN polyp_NN number_NN ._.
        Similarly_RB ,_, Ritland_NNP and_CC Gendler_NNP [_NN 34_CD ]_NN reported_VBD that_DT
        administration_NN of_IN piroxicam_NN (_( 200_CD ppm_NN in_IN diet_NN )_) to_TO 10_CD -_: 13_CD week_NN
        old_JJ 
        Min_NNP /_NN +_NN mice_NNS for_IN 6_CD or_CC more_JJR days_NNS
        resulted_VBD in_IN maximal_NN tumour_NN number_NN suppression_NN (_( >_NN 90_CD %_NN )_) ._.
        Finally_RB ,_, 
        R_NN -_: flurbiprofen_NN (_( 10_CD mg_NN /_NN kg_NN /_NN day_NN )_) orally_RB
        administered_VBN to_TO 
        Min_NNP /_NN +_NN for_IN 42_CD days_NNS starting_VBG at_IN 10_CD
        weeks_NNS of_IN age_NN was_VBD also_RB able_JJ to_TO decrease_VB tumour_NN number_NN by_IN
        greater_JJR than_IN 58_CD %_NN [_NN 11_CD ]_NN ._.
        Various_JJ studies_NNS have_VBP reported_VBN increased_VBN levels_NNS of_IN
        prostaglandins_NNS and_CC COX-_NNP 2_CD expression_NN in_IN colorectal_NN adenomas_NNS
        and_CC adenocarcinomas_NNS obtained_VBD both_DT from_IN animals_NNS [_NN 40_CD 41_CD ]_NN
        and_CC humans_NNS [_NN 42_CD 43_CD 44_CD ]_NN ._. These_DT findings_NNS have_VBP lead_VBN to_TO the_DT
        implication_NN that_IN COX-_NNP 2_CD plays_VBZ an_DT important_JJ role_NN in_IN
        intestinal_NN neoplasia_NN and_CC that_IN the_DT anti-neoplastic_JJ effects_NNS
        of_IN NSAIDs_NNP are_VBP attributable_JJ to_TO their_PRP$ ability_NN to_TO inhibit_VB
        COX-_NNP 2_CD ._. In_IN light_NN of_IN this_DT information_NN ,_, the_DT mechanism_NN by_IN which_WDT
        aspirin_NN and_CC other_JJ NSAIDs_NNP inhibit_VB colorectal_NN cancer_NN
        progression_NN has_VBZ not_RB been_VBN fully_RB elucidated_JJ and_CC cannot_NN simply_RB
        be_VB equated_VBN to_TO the_DT suppression_NN of_IN COX-_NNP 2_CD activity_NN ._. Shiff_NNP and_CC
        Rigas_NNP [_NN 45_CD ]_NN indicate_VBP that_IN NSAIDs_NNP may_MD to_TO affect_VB colorectal_NN
        cancer_NN development_NN via_IN one_CD or_CC more_JJR of_IN the_DT following_VBG four_CD
        areas_NNS :_: (_( 1_LS )_) COX-mediated_NNP carcinogen_NN activation_NN ,_, (_( 2_LS )_) cell_NN
        proliferation_NN ,_, (_( 3_LS )_) apoptosis_NNS and_CC (_( 4_LS )_) immune_JJ surveillance_NN ._.
        Within_IN these_DT potential_JJ mechanisms_NNS exists_VBZ the_DT possibility_NN
        for_IN both_DT COX-dependent_NNP and_CC -_: independent_JJ mechanisms_NNS ._. In_IN the_DT
        current_JJ study_NN we_PRP also_RB examined_VBD COX-activity_NNP and_CC apoptosis_NNS ._.
        The_DT treatment_NN regime_NN employed_VBN was_VBD sufficient_JJ to_TO attenuate_NN
        COX_NNP activity_NN by_IN 75_CD %_NN and_CC increased_VBD the_DT number_NN of_IN apoptotic_JJ
        bodies_NNS within_IN tumours_NNS by_IN greater_JJR than_IN 2_CD -_: fold_VB ._. Similar_JJ
        findings_NNS were_VBD reported_VBN by_IN Mahmoud_NNP 
        et_CC al_NN ._. [_NN 9_CD ]_NN using_VBG an_DT equivalent_NN
        dose_NN of_IN aspirin_NN in_IN a_DT prevention_NN strategy_NN ._. These_DT authors_NNS
        demonstrated_VBD a_DT >_NN 50_CD %_NN reduction_NN in_IN small_JJ intestinal_NN tumour_NN
        number_NN and_CC PGE_NNP 
        2_CD content_NN and_CC a_DT >_NN 4_CD -_: fold_VB increase_NN in_IN
        apoptosis_NNS ._. Contrary_JJ to_TO the_DT similarities_NNS seen_VBN in_IN
        COX-inhibition_NNP and_CC increased_VBN apoptosis_NNS ,_, the_DT present_JJ study_NN
        saw_VBD no_DT effect_NN on_IN tumour_NN number_NN or_CC size_NN ._. The_DT discordant_JJ
        effect_NN seen_VBN between_IN the_DT current_JJ study_NN and_CC that_IN of_IN Mahmoud_NNP 
        et_CC al_NN ._. [_NN 9_CD ]_NN are_VBP difficult_JJ to_TO
        explain_VB ._. The_DT duration_NN and_CC timing_NN of_IN treatment_NN (_( i_NNP ._. e_SYM ._. ,_,
        prevention_NN vs_NNS ._. treatment_NN )_) would_MD seem_VB the_DT most_RBS likely_JJ
        explanation_NN ._. This_DT possibility_NN has_VBZ also_RB been_VBN eluded_VBD in_IN
        epidemiological_JJ studies_NNS ._. The_DT Physicians_NNPS '_POS Health_NNP Study_NNP found_VBD
        no_DT significant_JJ reduction_NN in_IN the_DT relative_JJ risk_NN of_IN developing_VBG
        colorectal_NN cancer_NN in_IN individuals_NNS consuming_NN 325_CD mg_NN of_IN
        aspirin_NN every_DT other_JJ day_NN for_IN 5_CD years_NNS [_NN 46_CD ]_NN ._. The_DT Nurses_NNP '_POS
        Health_NNP Study_NNP reported_VBD that_IN a_DT significant_JJ decrease_NN in_IN risk_NN
        was_VBD only_RB seen_VBN in_IN women_NNS who_WP took_VBD aspirin_NN on_IN a_DT regular_JJ basis_NN
        for_IN 10_CD or_CC more_JJR years_NNS [_NN 13_CD ]_NN ._. Whether_IN this_DT simple_JJ
        explanation_NN accounts_NNS for_IN the_DT difference_NN in_IN results_NNS reported_VBD
        here_RB and_CC by_IN Mahmoud_NNP 
        et_CC al_NN ._. [_NN 9_CD ]_NN does_VBZ not_RB seem_VB likely_JJ ._.
        As_IN stated_VBN earlier_JJR ,_, three_CD previous_JJ studies_NNS employing_VBG
        prevention_NN strategies_NNS and_CC higher_JJR doses_NNS of_IN aspirin_NN also_RB
        found_VBD no_DT effect_NN on_IN tumour_NN burden_NN [_NN 36_CD 37_CD 38_CD ]_NN ._. Perhaps_RB a_DT
        similar_JJ discordant_JJ effect_NN will_MD appear_VB in_IN human_JJ studies_NNS as_IN
        results_NNS are_VBP released_VBN from_IN the_DT currently_RB ongoing_JJ clinical_JJ
        trials_NNS [_NN 33_CD ]_NN ._. If_IN such_JJ a_DT situation_NN does_VBZ arise_VB ,_, it_PRP could_MD
        indicate_VB that_DT aspirin_NN might_MD not_RB be_VB the_DT NSAID_NNP of_IN choice_NN for_IN
        colorectal_NN cancer_NN therapy_NN ._. In_IN contrast_NN ,_, to_TO date_NN no_DT
        conflicting_JJ data_NN have_VBP been_VBN published_VBN regarding_VBG the_DT use_NN of_IN
        sulindac_NN ._. Sulindac_NNP has_VBZ been_VBN shown_VBN to_TO be_VB efficacious_JJ both_DT in_IN
        rodent_NN models_NNS of_IN FAP_NNP and_CC in_IN human_JJ FAP_NNP patients_NNS ._.
        Although_IN no_DT change_NN was_VBD seen_VBN in_IN tumour_NN number_NN or_CC size_NN ,_,
        the_DT significant_JJ increase_NN seen_VBN in_IN apoptosis_NNS might_MD imply_VB that_DT
        aspirin_NN could_MD still_RB hold_VB utility_NN in_IN treating_VBG colorectal_NN
        cancer_NN ._. The_DT present_JJ study_NN would_MD suggest_VB that_DT aspirin_NN has_VBZ
        little_JJ or_CC no_DT use_NN as_IN a_DT stand-alone_JJ therapy_NN ,_, but_CC could_MD
        present_VB a_DT viable_JJ option_NN in_IN combination_NN chemotherapy_NN ._. Recent_JJ
        reports_NNS by_IN Torrance_NNP 
        et_CC al_NN ._. [_NN 47_CD ]_NN and_CC Mann_NNP 
        et_CC al_NN ._. [_NN 48_CD ]_NN demonstrate_VB that_DT
        combinatorial_NN therapy_NN comprised_VBN of_IN a_DT COX_NNP inhibitor_NN and_CC
        growth_NN factor_NN receptor_NN inhibitors_NNS resulted_VBD in_IN synergistic_JJ
        anti-tumour_JJ activity_NN ._. In_IN fact_NN ,_, the_DT study_NN conducted_VBN by_IN
        Torrance_NNP and_CC colleagues_NNS [_NN 47_CD ]_NN demonstrated_VBN that_IN doses_NNS of_IN
        sulindac_NN (_( 5_CD mg_NN /_NN kg_NN )_) found_VBD to_TO be_VB ineffective_JJ as_IN stand-alone_JJ
        chemotherapy_NN in_IN the_DT Min_NNP /_NN +_NN model_NN became_VBD extremely_RB potent_JJ
        when_WRB combined_VBN with_IN an_DT epidermal_NN growth_NN factor_NN receptor_NN
        kinase_NN inhibitor_NN ._. The_DT combination_NN therapy_NN was_VBD able_JJ to_TO
        completely_RB abolish_VB all_DT macroscopically_RB visible_JJ tumours_NNS in_IN
        47_CD %_NN of_IN the_DT animals_NNS treated_VBD [_NN 47_CD ]_NN ._. This_DT could_MD prove_VB to_TO be_VB
        very_RB advantageous_JJ since_IN it_PRP may_MD allow_VB for_IN lower_JJR doses_NNS of_IN
        NSAIDs_NNP to_TO be_VB used_VBN ,_, thereby_RB limiting_VBG the_DT adverse_JJ effects_NNS
        associated_VBN with_IN long_JJ term_NN NSAID_NNP use_NN ._. Pursuing_NNP future_JJ
        research_NN into_IN the_DT combinatorial_NN
        chemopreventive_JJ /_NN chemotherapeutic_JJ potential_NN of_IN aspirin_NN may_MD
        be_VB of_IN greater_JJR value_NN than_IN trying_VBG to_TO account_VB for_IN the_DT
        discordant_JJ effect_NN ._.
      
      
        Conclusions_NNP
        Despite_IN abundant_JJ evidence_NN from_IN epidemiological_JJ ,_, clinical_JJ
        and_CC animal_NN studies_NNS regarding_VBG the_DT potential_JJ utility_NN of_IN
        aspirin_NN as_IN a_DT chemotherapeutic_JJ agent_NN for_IN colorectal_NN cancer_NN ,_,
        the_DT current_JJ study_NN found_VBD no_DT change_NN in_IN tumour_NN burden_NN in_IN the_DT
        extensively_RB used_VBN 
        Min_NNP /_NN +_NN murine_NN model_NN of_IN colon_NN cancer_NN ._.
        The_DT findings_NNS that_WDT aspirin_NN was_VBD still_RB able_JJ to_TO significantly_RB
        increase_VB the_DT number_NN of_IN apoptotic_JJ cells_NNS within_IN tumours_NNS and_CC
        lower_JJR prostaglandin_NN levels_NNS suggests_VBZ that_IN it_PRP may_MD be_VB better_RBR
        suited_VBN to_TO combinatorial_NN therapy_NN ,_, but_CC its_PRP$ utility_NN as_IN a_DT
        stand-alone_JJ modality_NN in_IN established_VBN GI_NNP cancer_NN is_VBZ
        questionable_JJ ._. Promising_NNP results_NNS have_VBP already_RB been_VBN attained_VBN
        in_IN animal_NN models_NNS using_VBG COX_NNP inhibitors_NNS as_IN co-therapies_JJ in_IN
        the_DT treatment_NN of_IN colorectal_NN cancer_NN and_CC present_VB a_DT valuable_JJ
        future_JJ research_NN direction_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Author_NN 's_POS contributions_NNS
        BKR_NNP performed_VBD the_DT animal_NN studies_NNS ,_, immunoassays_NNS and_CC
        drafted_VBD the_DT manuscript_NN ._. XJZ_NNP carried_VBD out_RP the_DT
        immunohistochemistry_NN and_CC aided_VBN with_IN tissue_NN collection_NN ._. MJS_NNP
        participated_VBD in_IN study_NN design_NN ,_, coordination_NN and_CC manuscript_NN
        preparation_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
